Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.
暂无分享,去创建一个
V. Gebski | D. Provencher | D. Eek | C. Scott | K. Tamura | M. Friedlander | F. Joly | M. Rodrigues | T. Huzarski | L. Wenzel | R. Bloomfield | A. Clamp | R. Penson | E. Pujade-Lauraine | E. Gibbs | L. Vidal | F. Hilpert | V. Salutari | M. O. Nicoletto | J. Korach